Restoring metabolic balance

Harnessing precision-targeted drug formulations for the treatment and prevention of metabolic disorders such as obesity and related diseases

Our Approach

Metabolic Diseases: A Global Epidemic

Metabolic disorders such as obesity or type 2 diabetes have presented as a health and economic problem of global proportions over the past 40 years. Perturbations of the endocrine balance are a hallmark of most of these disorders. Safely restoring metabolic balance is the key to treating and preventing them.

LEARN MORE

APH-012

We believe that our lead candidate, APH-012, has the potential to revolutionize the treatment of metabolic diseases like obesity and type 2 diabetes. APH-012 uniquely induces the release of the full spectrum of enteral hormones that control appetite, hunger, satiety, glucose metabolism, and other homeostatic functions.

LEARN MORE

Programs

Phase 2 Trial in Obesity

APH-012 is being evaluated in a Phase 2 proof-of-concept study in individuals with obesity The trial will evaluate APH-012’s ability to change individual’s percent weight compared to placebo, in addition to other key parameters which are hallmarks of multiple metabolic diseases closely associated with obesity.

LEARN MORE

News

Aphaia Pharma to Participate in the LSX Leaders Inv€$tival Showcase

11/07/2022

Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of metabolic diseases, today announced that it will participate in the LSX Leaders Inv€$tival Showcase, to be held November 14, 2022, in London as the pre-day to the Jefferies London Healthcare Conference, November 15-17, 2022.

First Patient in Phase 2 Study of APH-012

10/27/2022

Aphaia Pharma Announces Enrollment of First Patient in Phase 2 Study of APH-012 for Chronic Weight Management in Individuals with Obesity
Aphaia Pharma, a clinical-stage biopharmaceutical company harnessing precision-targeted drug delivery technology for the treatment and prevention of metabolic diseases, today announced that it has enrolled the first patient as part of a Phase 2 study evaluating the safety and efficacy of its lead drug candidate, APH-012, to induce weight loss in individuals with obesity.

All news